Cyclohexyl beta-hydroxy alkyl amines and medical uses thereof
US-2024390298-A1 · Nov 28, 2024 · US
Methods for treating lung cancer
US9744145B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9744145-B1 |
| Application number | US-201715406798-A |
| Country | US |
| Kind code | B1 |
| Filing date | Jan 16, 2017 |
| Priority date | Jan 16, 2017 |
| Publication date | Aug 29, 2017 |
| Grant date | Aug 29, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides a method of treating lung cancer including administering a therapeutically effective amount of a compound of 0089-0022 formula I to a subject in need thereof. The compound activates pyruvate kinase M2 isoform (PKM2) to treat the lung cancer. In one example, the lung cancer is Non-Small Cell Lung Cancer (NSCLC).
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating lung cancer in a subject in need thereof, comprising: administering a therapeutically effective amount of a compound to the subject to treat the lung cancer, wherein the compound is presented by formula I 2. The method of claim 1 , wherein the lung cancer is Non-Small Cell Lung Cancer. 3. The method of claim 1 , wherein the lung cancer is wild type epidermal growth factor receptor (EGFR). 4. The method of claim 1 , wherein the lung cancer includes EGFR L858R and T790M mutant. 5. The method of claim 1 , wherein the compound activates pyruvate kinase M2 isoform (PKM2) to treat the lung cancer. 6. The method of claim 1 , wherein the method further comprises: treating the cancer for 48 hours with a concentration of formula I less than 20.22 μM. 7. The method of claim 1 , wherein the method further comprises: treating the cancer for 72 hours with a concentration of formula I less than 15.40 μM. 8. A method of treating cancer in a subject in need thereof comprising: administering a therapeutically effective amount of a compound to the patient to treat the cancer, wherein the cancer includes wild type epidermal growth factor receptor (EGFR), or EGFR L858R and T790M mutant, and the compound is presented by formula I 9. The method of claim 8 , wherein the compound activates pyruvate kinase M2 isoform (PKM2) to treat the cancer. 10. The method of claim 8 , wherein the cancer is lung cancer. 11. The method of claim 8 , wherein the cancer is Non-Small Cell Lung Cancer (NSCLC). 12. The method of claim 8 , wherein the method further comprises: treating the cancer for 48 hours with a concentration of formula I less than 20.22 μM. 13. The method of claim 8 , wherein the method further comprises: treating the cancer for 72 hours with a concentration of formula I less than 15.40 μM. 14. A method of treating cancer in a subject in need thereof comprising: diagnosing the subject having cancers including wild type epidermal growth factor receptor (EGFR), or EGFR L858R and T790M mutant; administering a therapeutically effective amount of a compound to the patient to treat the cancer, and the compound is presented by formula I 15. The method of claim 14 , wherein the compound activates pyruvate kinase M2 isoform (PKM2) to treat the cancer. 16. The method of claim 14 , wherein the cancer is lung cancer. 17. The method of claim 14 , wherein the cancer is Non-Small Cell Lung Cancer (NSCLC). 18. The method of claim 14 , wherein the method further comprises: treating the cancer for 48 hours with a concentration of formula I less than 20.22 μM. 19. The method of claim 14 , wherein the method further comprises: treating the cancer for 72 hours with a concentration of formula I less than 15.40 μM.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9744145B1 cover?
- This invention provides a method of treating lung cancer including administering a therapeutically effective amount of a compound of 0089-0022 formula I to a subject in need thereof. The compound activates pyruvate kinase M2 isoform (PKM2) to treat the lung cancer. In one example, the lung cancer is Non-Small Cell Lung Cancer (NSCLC).
- Who is the assignee on this patent?
- Univ Macau Sci & Tech
- What technology area does this patent fall under?
- Primary CPC classification A61K31/18. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).